Surface Oncology Inc. (NASDAQ: SURF) is 245.74% higher on its value in year-to-date trading and has touched a low of $1.15 and a high of $7.66 in the current 52-week trading range. The SURF stock was last observed hovering at around $6.50 in the recent trading session, with the current loss setting it -0.05% off its average median price target of $10.00 for the next 12 months. It is also 46.25% off the consensus price target high of $12.00 offered by 4 analysts, but current levels are 28.33% higher than the price target low of $9.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $6.45, the stock is 23.11% and 51.06% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.46 million and changing -0.77% at the moment leaves the stock 141.28% off its SMA200. SURF registered 147.15% gain for a year compared to 6-month gain of 242.11%. The firm has a 50-day simple moving average (SMA 50) of $5.02 and a 200-day simple moving average (SMA200) of $3.17.
The stock witnessed a 38.30% loss in the last 1 month and extending the period to 3 months gives it a 273.56%, and is 16.28% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.37% over the week and 11.39% over the month.
Surface Oncology Inc. (SURF) has around 49 employees, a market worth around $190.78M and $39.50M in sales. Profit margin for the company is -70.90%. Distance from 52-week low is 460.87% and -15.80% from its 52-week high. The company has generated returns on investments over the last 12 months (-88.70%).
Surface Oncology Inc. (SURF) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Surface Oncology Inc. (SURF) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 1 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Surface Oncology Inc. is expected to release its quarterly report on 08/05/2020 and quarterly earnings per share for the current quarter are estimated at -$0.48.The EPS is expected to shrink by -495.10% this year, but quarterly earnings will post 152.10% year-over-year.
Surface Oncology Inc. (SURF) Top Institutional Holders
46 institutions hold shares in Surface Oncology Inc. (SURF), with 4.75M shares held by insiders accounting for 16.76% while institutional investors hold 75.38% of the company’s shares. The shares outstanding are 27.98M, and float is at 27.65M with Short Float at 2.61%. Institutions hold 62.75% of the Float.
Surface Oncology Inc. (SURF) Insider Activity
A total of 9 insider transactions have happened at Surface Oncology Inc. (SURF) in the last six months, with sales accounting for 1 and purchases happening 8 times. The most recent transaction is an insider sale by New Enterprise Associates 14, , the company’s 10% Owner. SEC filings show that New Enterprise Associates 14, sold 420,000 shares of the company’s common stock on May 20 at a price of $3.66 per share for a total of $1.54 million. Following the sale, the insider now owns 2.89 million shares.
Surface Oncology Inc. disclosed in a document filed with the SEC on Feb 05 that Goater Jeff (Chief Executive Officer) bought a total of 5,000 shares of the company’s common stock. The trade occurred on Feb 05 and was made at $3.23 per share for $16150.0. Following the transaction, the insider now directly holds 0.26 million shares of the SURF stock.